| 相婷,邵平.小剂量托法替布联合雷公藤对甲氨蝶呤应答不足RA患者炎症指标及关节滑膜侵蚀的影响.[J].中南医学科学杂志.,2024,(4):614-616, 641. |
| 小剂量托法替布联合雷公藤对甲氨蝶呤应答不足RA患者炎症指标及关节滑膜侵蚀的影响 |
| Effects of low-dose tofacitinib combined with tripterygium wilfordii on inflammatory markers and synovial erosion in RA patients with inadequate methotrexate response |
| 投稿时间：2024-02-22 修订日期：2024-05-15 |
| DOI：10.15972/j.cnki.43-1509/r.2024.04.027 |
| 中文关键词: 类风湿关节炎 甲氨蝶呤 托法替布 雷公藤 炎症 关节滑膜侵蚀 |
| 英文关键词:rheumatoid arthritis methotrexate tofacitinib tripterygium wilfordii inflammation synovial erosion |
| 基金项目:连云港市老龄健康科研项目(L202115) |
|
| 摘要点击次数: 108 |
| 全文下载次数: 115 |
| 中文摘要: |
| 目的观察小剂量托法替布联合雷公藤对甲氨蝶呤应答不足类风湿关节炎(RA)患者炎症指标及关节滑膜侵蚀的影响。 方法选取108例甲氨蝶呤应答不足RA患者,按照入院先后顺序均分为对照组和观察组。两组均予以雷公藤多苷片治疗,观察组在此基础上联合小剂量托法替布治疗。比较两组治疗前后疗效指标评分、炎症指标水平、症状、关节滑膜侵蚀情况以及不良反应发生情况。 结果治疗后,两组疗效指标评分、炎症指标水平均较治疗前降低,且观察组低于对照组(P＜0.05)；两组症状、关节滑膜侵蚀情况较治疗前均明显改善(P＜0.05),且观察组改善情况优于对照组(P＜0.05)。两组不良反应发生率比较,差异无显著性(P＞0.05)。 结论小剂量托法替布联合雷公藤较单用雷公藤可以显著降低甲氨蝶呤应答不足RA患者炎症指标水平,改善关节滑膜侵蚀程度,提高临床疗效。 |
| 英文摘要: |
| AimTo explore the effects of low-dose tofacitinib combined with tripterygium wilfordii on inflammatory indicators and synovial erosion in patients with rheumatoid arthritis (RA) with insufficient response to methotrexate. Methods108 RA patients with insufficient response to methotrexate in our hospital were selected and divided into a control group and an observation group according to the order of hospitalization. Both groups were treated with tripterygium wilfordii glycoside tablets, while the observation group was additionally treated with low-dose tofacitinib on this basis. The efficacy indicators before and after treatment, symptom status, inflammation indicators, joint synovial erosion, and adverse reactions between two groups were compared. ResultsAfter treatment, the efficacy index score and inflammation index level in both groups were lower than them before treatment, and the observation group was lower than the control group (P＜0.05). The symptoms and joint synovial erosion in both groups were significantly improved than them before treatment (P＜0.05), and the improvement in the observation group was better than that in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionLow-dose tofacitinib combined with tripterygium wilfordii can better regulate inflammatory indicators, improve joint synovial erosion, and enhance clinical efficacy in RA patients with insufficient response to methotrexate. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |